Patient group input requested for a new Joint Assessment on a medicinal product for acute myeloid leukaemia (AML).
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]
PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing authorisation for pretomanide (pretomanid FGK) in combination with bedaquiline and linezolid for the treatment […]
RCR01-RCR15 Covid-19 Rolling Collaborative Review – Second round of reviews now available
As part of its response to the Covid-19 pandemic, EUnetHTA is working to output ‘Rolling Collaborative Reviews (RCR)’. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic health technologies relevant to the management of the current pandemic. EUnetHTA is pleased to announce […]
Final Week – EUnetHTA Open Call for Early Dialogue Requests
The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open Call was opened on July 3, 2020 and will run through to August 15, […]
OTCA23 Final Assessment Report “Biodegradable rectum spacers to reduce toxicity for prostate cancer” now available
The Other Technologies Collaborative Assessment OTCA23 final assessment report “Biodegradable rectum spacers to reduce toxicity for prostate cancer”, together with related documentation, is now available for access. The assessed technology is biodegradable rectum spacers added to conventional radiotherapy to (temporarily) position the prostate away from the rectum with the aim of reducing the side effects […]
PTJA12 – Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA12 – on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary AML in adult patients who are not candidates for standard […]
EUnetHTA Implementation – Final Report now available
The Final Report on Implementation, a deliverable of EUnetHTA Joint Action 3 (2016-2021), explores the use of joint assessments (JA) and collaborative assessments (CA) during JA3 and compares this with the use of assessment products during Joint Action 2 (2012-2015). By examining how JA and CA processes have affected implementation, the report outlines the extent […]
EUnetHTA Covid-19 Response
To help in the development of a coordinated response to the Covid-19 pandemic, it is essential that researched, timely and reliable information can be made available to all stakeholders, whether healthcare professionals or members of the public. With this in mind, EUnetHTA has taken the decision to prioritise Covid-19-related initiatives above other work for the […]
EUnetHTA Open Call for Early Dialogue Requests
The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open Call will remain open from July 3, 2020 through to August 15, 2020. Once […]
OTCA24 Final Assessment Report now available.
The final assessment report and related documentation is now available for Rapid Relative Effectiveness Assessment OTCA24 ‘The 24-hour blood pressure measurement device Mobil-O- Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment’. Mobil-O-Graph® is a blood pressure measuring device that measures peripheral blood pressure. It can be coupled […]
